Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat lymphoma: drug duo aims to shrink tumors and delay progression

NCT ID NCT05171647

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adults with certain lymphoma subtypes will be randomly assigned to one of the two treatment groups. The main goals are to see how many patients have their tumors shrink or disappear and how long they live without the cancer getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

  • Anadolu Health Center

    Kocaeli, 41400, Turkey (Türkiye)

  • Ankara University Medical Faculty

    Ankara, 06100, Turkey (Türkiye)

  • Ascension Seton Infusion Center

    Austin, Texas, 78712, United States

  • Cancer Center, Sun Yat-sen University of Medical Sciences

    Guangzhou, 510060, China

  • Chiang Mai Uni Hospital

    Chiang Mai, 50200, Thailand

  • Chum Hopital Notre Dame

    Montreal, Quebec, H2L 4M1, Canada

  • Chungnam National University Hospital

    Daejeon, 35015, South Korea

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • D'or Instituto de Pesquisa e Educação

    São Paulo, Brazil

  • Dokuz Eylul Universitesi Tip Fakultesi

    Lzmir, 35340, Turkey (Türkiye)

  • FUNDALEU

    Buenos Aires, C1114AAN, Argentina

  • Fujian Medical University Union Hospital

    Fuzhou, 350001, China

  • Hamilton Health Sciences - Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2, Canada

  • Henan Cancer Hospital

    Zhengzhou, 450008, China

  • Hokkaido University Hospital

    Hokkaido, 060-8648, Japan

  • Hospital Aleman

    Buenos Aires, 1118, Argentina

  • Hospital Erasto Gaertner

    Curitiba, Paraná, 81520-060, Brazil

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma Buenos Aires, C1181ACH, Argentina

  • Hospital Sao Jose

    São Paulo, São Paulo, 01323-030, Brazil

  • Hospital Universitario Dr. Jose E. Gonzalez

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Hospital das Clínicas FMRP-USP

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Ichilov Sourasky Medical Center

    Tel Aviv, 6423906, Israel

  • Instituto Alexander Fleming

    Buenos Aires, 1426, Argentina

  • Instituto Nacional de Cancerologia

    Distrito Federal, 14080, Mexico

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    México, Mexico

  • Instituto Regional de Enfermedades Neoplásicas del Sur

    Arequipa, 5154, Peru

  • Kindai University Hospital

    Osaka, 589-8511, Japan

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medipol Mega Üniversite Hastanesi Göztepe

    Istanbul, 34214, Turkey (Türkiye)

  • Middlemore Clinical Trials

    Auckland, New Zealand

  • Oncosalud Sac

    Lima, 41, Peru

  • Ondokuz Mayis Univ. Med. Fac.

    Samsun, 55139, Turkey (Türkiye)

  • Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Sichuan Cancer Hospital

    Chengdu, 610041, China

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Soroka Medical Center

    Beersheba, 8410101, Israel

  • Srinagarind Hospital, Khon Kaen Uni

    Khon Kaen, 40002, Thailand

  • St. Luke's Hospital

    Chesterfield, Missouri, 63017, United States

  • Superare Centro de Infusion S.A. de C.V.

    Mexico City, Mexico CITY (federal District), 11550, Mexico

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135-8550, Japan

  • Tianjin Cancer Hospital

    Tianjin, 300060, China

  • Tohoku University Hospital

    Miyagi, 980-8574, Japan

  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

    Wuhan, 430030, China

  • Yamagata University Hospital

    Yamagata, 990-9585, Japan

  • Yeouido St. Mary's Hospital

    Seoul, 07345, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.